This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acadia Healthcare (ACHC) to Build Behavioral Health Unit in Mesa
by Zacks Equity Research
Acadia Healthcare (ACHC) begins the construction of its Mesa-based behavioral health hospital to address the inadequacy of behavioral healthcare resources in Arizona.
Will Biden's Tax Hike Plan Extend Medicare's Life to 2050?
by Kaibalya Pravo Dey
U.S. President Joe Biden's proposal is also likely to enhance Medicare's ability to negotiate prices for drugs.
Humana Inc. (HUM) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Humana (HUM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Humana (HUM) Ties Up To Offer Value-Based Care to MA Members
by Zacks Equity Research
Humana (HUM) inks a 10-year collaboration with Aledade to ensure continued value-based primary care to its Medicare Advantage members from Aledade-backed physicians.
Humana (HUM) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $495.76, moving -0.08% from the previous trading session.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica
by Zacks Equity Research
The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.
Humana (HUM) Exits Business Line to Focus More on Core Units
by Zacks Equity Research
Humana (HUM) will depart from the Employer Group Commercial Medical Products business so that it can invest more funds to grow its core Insurance business lines.
The Zacks Analyst Blog Highlights Humana Cenovus Energy, Autohome, EnPro Industries and Merchants Bancorp
by Zacks Equity Research
Humana Cenovus Energy, Autohome, EnPro Industries, and Merchants Bancorp are part of the Zacks Analyst top Blog.
5 Stocks With Recent Dividend Hike for a Stable Portfolio
by Nalak Das
Dividend-paying stocks should be in demand as investors will try to safeguard their portfolios. Five of them are: HUM, CVE, ATHM, NPO and MBIN.
Investors Heavily Search Humana Inc. (HUM): Here is What You Need to Know
by Zacks Equity Research
Humana (HUM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Humana (HUM) Rewards Shareholders With a 12.4% Dividend Hike
by Zacks Equity Research
Humana's (HUM) capital position with strong cash-generating abilities and a solid balance sheet will likely sustain its shareholder-friendly moves.
Tenet (THC) Q4 Earnings Beat on Ambulatory Care Strength
by Zacks Equity Research
Tenet Healthcare's (THC) bottom line deteriorates due to higher operating expenses, partially offset by an improving Ambulatory Care segment.
Encompass Health's (EHC) Shares Up 3% on Q4 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results reflect growing patient volumes and reimbursement rates. Management expects 2023 adjusted EPS within $2.87-$3.16, higher than $2.85 in 2022.
Here is What to Know Beyond Why Humana Inc. (HUM) is a Trending Stock
by Zacks Equity Research
Humana (HUM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter results indicate higher skilled services revenue and improved occupancies, partly offset by the increased cost of services.
Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up
by Zacks Equity Research
Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.
Humana (HUM) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat
by Zacks Equity Research
Humana's (HUM) fourth-quarter results benefit from solid premiums from its individual Medicare Advantage business and the sound performance of the two newly formed segments.
Humana (HUM) Tops Q4 Earnings Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 10.96% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Humana's (HUM) Q4 Earnings Beat on Healthcare Services?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $499.36, moving -0.57% from the previous trading session.
Humana Inc. (HUM) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Humana (HUM) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Humana (HUM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.